Clinical trials of pyruvate kinase activators in thalassemia
| Category . | Phase . | Drug . | N . | Duration . | Identifier . | Status . |
|---|---|---|---|---|---|---|
| NTDT | 2 (single-arm, open-label) | Mitapivat | 20 | 24 weeks | NCT03692052 | Completed |
| Etavopivat | 20 | 48 weeks | NCT04987489 (cohort C) | Ongoing | ||
| 3 (double-blind RCT) | Mitapivat: placebo (2:1) | 171 | 24 weeks | NCT04770753 | Ongoing | |
| TDT | 2 (single-arm, open-label) | Etavopivat | 20 | 48 weeks | NCT04987489 (cohort B) | Ongoing |
| 3 (double-blind RCT) | Mitapivat: placebo (2:1) | 240 | 48 weeks | NCT04770779 | Ongoing |
| Category . | Phase . | Drug . | N . | Duration . | Identifier . | Status . |
|---|---|---|---|---|---|---|
| NTDT | 2 (single-arm, open-label) | Mitapivat | 20 | 24 weeks | NCT03692052 | Completed |
| Etavopivat | 20 | 48 weeks | NCT04987489 (cohort C) | Ongoing | ||
| 3 (double-blind RCT) | Mitapivat: placebo (2:1) | 171 | 24 weeks | NCT04770753 | Ongoing | |
| TDT | 2 (single-arm, open-label) | Etavopivat | 20 | 48 weeks | NCT04987489 (cohort B) | Ongoing |
| 3 (double-blind RCT) | Mitapivat: placebo (2:1) | 240 | 48 weeks | NCT04770779 | Ongoing |
RCT, randomized controlled trial.